Fierce Biotech April 12, 2024
Enlivex Therapeutics had a message Friday for investors who halved its share price: You’re misreading our data. The cell therapy developer blamed imbalances between cohorts for the mixed results—and contended the effect on a small subgroup of sepsis patients suggests the candidate has a future.
The phase 2 clinical trial compared Allocetra, an off-the-shelf cell therapy that is designed to reprogram macrophages, to placebo in the treatment of organ failure in adult sepsis patients. Enlivex takes cells from healthy donors and makes them express an “eat me” signal. After administration, macrophages duly eat the cells and homeostasis is restored. That’s the idea, anyway.
Whether the phase 2 trial supports the efficacy of the mechanism is a point of disagreement...
Today's Sponsors
Today's Sponsor